Patients intravenously received at least 1 dose of either ENHERTU (N=125) 6.4 mg/kg every 3 weeks or either irinotecan (N=55) 150 mg/m2 biweekly or paclitaxel (N=7) 80 mg/m2 weekly for 3 weeks.

Patients intravenously received at least one dose of either ENHERTU (N=125) 6.4 mg/kg every 3 weeks or either irinotecan (N=55) 150 mg/m2 biweekly or paclitaxel (N=7) 80 mg/m2 weekly for 3 weeks.

Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter ...

Dose reductions occurred in 32% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were neutropenia, decreased appetite, fatigue, nausea ...

Enhertu was administered at a dose of 5.4 mg/kg every three weeks in all groups. The primary end point was confirmed overall response rate by investigator. Secondary end points included disease ...

The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least 1 dose of ENHERTU 5.4 mg/kg intravenously once every 3 weeks ...

Enhertu is administered via intravenous (IV) infusion once every 3 weeks ... The product is supplied as a preservative-free lyophilized powder for IV infusion in 100mg single-dose vials.

Dose interruptions of ENHERTU due to adverse reactions occurred in 23% of patients. Adverse reactions which required dose interruption (>2%) included neutropenia and ILD/pneumonitis.

Regarding safety, Enhertu carries a Boxed Warning for interstitial lung disease and embryo-fetal toxicity. ... The product will be available within the coming weeks as 100mg single-dose vials.

Daiichi Sankyo and AstraZeneca’s ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in primary analysis ENHERTU provided a median progression free ...

Side effects led to dose reduction or interruption for 27% and 51.5% of patients, and discontinuation for 9.5% of patients. Six patients experienced side effects that proved fatal and five were ...

Dose interruptions of ENHERTU due to adverse reactions occurred in 23% of patients. Adverse reactions which required dose interruption (>2%) included neutropenia and ILD/pneumonitis.